# US 7,626,031 B2 · Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,626,031 B2
- Document ID: US7626031B2
- Status: Granted
- Kind: B2
- Application number: 10/533,555
- Filed: 2003-11-14
- Published: 2006-06-08
- Granted: 2009-12-01
- Earliest claimed: 2002-11-15
- Assignees: Symphony Evolution, Inc.
- Inventors: Wei Xu; Erick Wang Co; John M. Nuss; Moon Hwan Kim; Rhett Ronald Klein; Donna Tra Le; Amy Lew Tsuhako; Jason Jevious Parks; Zhaoyang Wen; Wei Cheng
- Web page: https://patentgrep.com/patent/US7626031B2

## CPC

- C07D 403/14: containing three or more hetero rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

## Claims

### Claim 1

A compound represented by formula I,
or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof, and wherein,
each W is CR1;
each R1 is independently selected from —H and —A—R7; provided one of R1 is —A—R7 and is located at the 5-position of the indolinone ring, wherein, only for said —A—R7, R7 must be a piperidin-4-yl, and where the nitrogen of the piperidin-4-yl of —A—R7 is optionally substituted with one group selected from alkyl, arylalkyl, pyrrolidinylethyl, piperidinylethyl, morpholinylethyl, and sulfonyl;
A is NH;
L is NR3;
Q is C;
R2 and R3 are each —H;
R4 and R5 are each independently selected from —H, —OR6, —NR6R7, —S(O)0-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —N(R6)SO2R6, —C(O)R7, —CN, —NO2, —NH2, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl; or
R4 and R5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R15;
R6 is selected from —H, and C1-8alkyl;
R7, for other than R7 in —A—R7, is selected from —H, and C1-8alkyl;
R8 is —H, —NO2, —CN, —OR6 or C1-8alkyl;
X is selected from one of the following formulae:
wherein m is zero to five, n is zero to three, and Z is CR10;
R10 is selected from —H, halogen, trihalomethyl, —NH2, —NO2, —OR6, —N═CNR6R7, —NR6R7, —N(R6)C(═NR8)NR6R7, —SR6, —S(O)1-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —C(O)N(OR6)R7, —C(═NR8)NR6R7, —N(R6)SO2R6, —C(O)R7, and R7;
K is O; and
each R15 is independently selected from —H, halogen, —OR6, and C1-8alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein X is
m is 0 to 3, and R10 is selected from —H, halogen, —NH2, —NO2, OR6, —N═CNR6R7, —NR6R7, —N(R6)C(═NR8)NR6R7, —SR6, —S(O)1-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —C(O)N(OR6)R7, —C(═NR8)NR6R7, —N(R6)SO2R6, —C(O)R7, and —C1-8alkyl; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 3

A compound of formula II:
or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof and where the compound is optionally as a pharmaceutically acceptable salt thereof;
wherein:
A is NH;
R7, in —A—R7,is piperidin-4-yl and is located on the 5-position of the indolinone ring;
wherein the ring nitrogen of R7 is substituted with a group R12; and
R12 is selected from a) —H, b) C1-8alkyl, c) —SO2R6, d) —SO2NR6R7, e) —CO2R6, f) —C(O)NR6R7, and g) —C(O)R7; and where the C1-8alkyl in b) is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, pyrrolidinylethyl, piperidinylethyl, morpholinylethyl, alkoxy, amino, alkylamino and dialkylamino;
R6 is selected from —H and C1-8alkyl;
R4 and R5 are each independently selected from —H, —OR6, —NR6R7, —S(O)0-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —N(R6)SO2R6, —C(O)R7, —CN, —NO2, —NH2, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl; or
R4 and R5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R15;
R10 is selected from —H, halogen, —NH2, —NO2, —OR6, —N═CNR6R7, —NR6R7, —N(R6)C(═NR8)NR6R7, —SR6, —S(O)1-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —C(O)N(OR6)R7, —C(═NR8)NR6R7, —N(R6)SO2R6, —C(O)R7, and C1-8alkyl;
m is 0 to 3;
R7, for other than R7 in A—R7, is selected from —H, and C1-8alkyl;
R8 is —H, —NO2, —CN, —OR6 or C1-8alkyl; and
each R15 is independently selected from —H, halogen, —OR6, and C1-8alkyl.

### Claim 4

A compound according to formula III,
or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;
where
R12 is a C1-4alkylene;
R13 is selected from —H, an alkoxy group, amino, alkylamino, dialkylamino, pyrrolidinylethyl, piperidinylethyl, and morpholinylethyl, and an heteroalicyclic, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, and dialkylamino group cannot be attached to a carbon of R12 which is directly attached to the ring nitrogen of the piperidine in formula III;
R4 and R5 are each independently selected from —H, —OR6, —NR6R7, —S(O)0-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —N(R6)SO2R6, —C(O)R7, —CN, —NO2, —NH2, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl; or
R4 and R5, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R15;
R6 is selected from —H and C1-8alkyl;
R7 is selected from —H, and C1-8alkyl;
R8 is —H, —NO2, —CN, —OR6, or C1-8alkyl;
R10 is selected from —H, halogen, —NH2, —NO2, —OR6, —N═CNR6R7, —NR6R7, —N(R6)C(═NR8)NR6R7, —SR6, —S(O)1-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —C(O)N(OR6)R7, —C(═NR8)NR6R7, —N(R6)SO2R6, —C(O)R7, and C1-8alkyl;
m is 0 to 3; and
each R15 is independently selected from —H, halogen, —OR6, and C1-8alkyl.

### Claim 5

A compound according to formula IIIa,
or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;
wherein R12 is a C2-4alkylene;
R13 is selected from —H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group pyrrolidinylethyl, piperidinylethyl, and morpholinylethyl;
R10 is selected from —H, halogen, perfluoroalkyl, —NH2, —NO2, —OR6, —N═CNR6R7, —NR6R7, —N(R6)C(═NR8)NR6R7, —SR6, —S(O)1-2R6, —SO2NR6R7, —CO2R6, —C(O)NR6R7, —C(O)N(OR6)R7, —C(═NR8)NR6R7, —N(R6)SO2R6, —C(O)R7;
R4 and R5 are each independently selected from —H, halogen, and C1-4alkyl; or R4 and R5 combined are a phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl;
m is 0-3;
R6 is selected from —H and C1-8alkyl;
R7 is selected from —H, and C1-8alkyl; and
R8 is —H, —NO2, —CN, —OR6 or C1-8alkyl.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein R12 is an ethylene; R10 is halogen; R4 and R5 are each independently selected from —H, halogen, and C1-2alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein each R10 is independently selected from fluorine and chlorine; R4 and R5 are each independently selected from —H and C1-2alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein each R10 is independently selected from fluorine and chlorine; R4 and R5 are each independently selected from —H and —CH3; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein R10 is fluorine; R4 and R5 are each independently selected from —H and —CH3; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The compound according to claim 9, selected from:
49
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-
imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
51
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-
methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-
one;
58
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-
imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
70
(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-
5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one;
78
(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-
[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one
82
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-
piperidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-
one;
83
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-
morpholin-4-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-
2-one;
84
(3Z)-5-({1-[2-(diethylamino)ethyl]piperidin-4-yl}amino)-3-[(3-
fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-
indol-2-one;
85
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-(2-
pyrrolidin-1-ylethyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-
one;
106
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-
methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-
one;
107
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-
imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; and
113
(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 3)

The Compound of claim 3 selected from
22
(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-
ylamino)-1,3-dihydro-2H-indol-2-one;
28
2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-
3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-
isoindole-1,3(2H)-dione;
30
(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-{[1-
(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one;
81
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-
4-ylamino)-1,3-dihydro-2H-indol-2-one; and
93
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-{[1-
(methylsulfonyl)piperidin-4-yl]amino}-1,3-dihydro-2H-indol-2-one;
and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 4)

The compound of claim 4 selected from
6
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-
benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-
indol-2-one;
12
(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
13
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-
methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
50
(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
52
(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
57
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-
methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-
2-one;
59
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-
propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
63
(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
64
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-
yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
67
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-
methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-
2H-indol-2-one;
69
(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one;
77
(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
86
(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-
methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
88
ethyl 2-{(Z)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-
yl}amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl}-4-methyl-
1H-imidazole-5-carboxylate;
94
(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one;
95
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-
1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
96
(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one; and
97
(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-
1,3-dihydro-2H-indol-2-one;
and where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 5)

The compound of claim 5 selected from
3
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-
benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-
one;
4
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-
yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
5
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{[5-(methyloxy)-1H-
benzimidazol-2-yl][4-(methyloxy)phenyl]methylidene}-1,3-
dihydro-2H-indol-2-one;
7
(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
8
(3Z)-3-{1H-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
9
(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
11
(3Z)-3-[(4-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-
[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
15
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-
(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
16
(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
17
(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-
[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
18
(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
19
(3Z)-3-[1H-benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
21
(3Z)-3-[(3-aminophenyl)(1H-benzimidazol-2-yl)methylidene]-5-
[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
23
3-((Z)-1H-benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-
oxo-1,2-dihydro-3H-indol-3-
ylidene}methyl)benzenecarboximidamide;
24
(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-
one;
26
(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
27
(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
29
(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-
(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
38
(3Z)-3-[1H-benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-
[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
39
(3Z)-3-{1H-benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-
5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one;
42
(3Z)-3-[1H-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-
5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one
45
(3Z)-3-[1H-benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
46
(3Z)-3-[1H-benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-
[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
47
(3Z)-3-[1H-benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-
[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one;
55
(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-
[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
56
(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(3,5-
difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-
dihydro-2H-indol-2-one;
60
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[4-
(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
61
(3E)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one;
62
(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1H-benzimidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one;
65
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-
(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-1,3-
dihydro-2H-indol-2-one;
71
(3Z)-3-{1H-imidazol-2-yl[4-
(trifluoromethyl)phenyl]methylidene}-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-
one;
72
(3Z)-3-[(5-chloro-1H-benzimidazol-2-yl)(phenyl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one;
89
(3Z)-3-[1H-imidazol-2-yl(phenyl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-
one;
90
(3Z)-3-{1H-imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one;
92
(3Z)-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1H-imidazol-2-
yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-
1,3-dihydro-2H-indol-2-one;
100
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-
(trifluoromethyl)phenyl](1H-imidazol-2-yl)methylidene]-
1,3-dihydro-2H-indol-2-one;
101
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{(4-methyl-1H-imidazol-2-
yl)[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2H-
indol-2-one;
103
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-
(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-
1,3-dihydro-2H-indol-2-one;
108
(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-
(trifluoromethyl)phenyl](4-methyl-1H-imidazol-2-yl)methylidene]-
1,3-dihydro-2H-indol-2-one;
114
(3Z)-3-[(3-trifluoromethylphenyl)(1H-imidazol-2-yl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
115
(3Z)-3-[(3-trifluoromethylphenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one;
116
(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-
dihydro-2H-indol-2-one; and
117
(3Z)-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-
2H-indol-2-one;
where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 8)

The compound of claim 8 selected from
40
(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-
one
41
(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-
(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-
one
48
(3Z)-3-[(3-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
53
(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
54
(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
66
(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
73
(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
74
(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
75
(3Z)-3-[(3,5-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one
76
(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-
1,3-dihydro-2H-indol-2-one
79
(3Z)-3-[(3,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-
({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one
80
(3Z)-3-[(3-chloro-4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-
5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-
indol-2-one
91
(3Z)-3-[(4-chlorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-
[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-
2-one
102
(3Z)-3-[(4-chlorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-
5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
104
(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
105
(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
109
(3Z)-3-[(2,3-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[(1-
ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
110
(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
111
(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
112
(3Z)-3-[(2,4-difluorophenyl)(1H-imidazol-2-yl)methylidene]-5-
[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one
118
(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1H-imidazol-2-
yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-
indol-2-one
where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 10)

The compound of claim 10 named (3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 10)

The compound of claim 10 named (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The Compound of claim 1 selected from (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2H-indol-2-one and (3Z)-3-{1H-imidazol-2-yl[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2H-indol-2-one; or a single geometric isomer thereof, optionally as a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1, 3, 4, 5, 10, 11, 12, 13, 14)

A pharmaceutical composition comprising a compound according to claim 1, 3, 4, 5, 10, 11, 12, 13, 14, or 17 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 15, 16)

A pharmaceutical composition comprising a compound according to claim 15 or 16, where the compound is optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
